Authors:
Bajdik, CD
Raboud, JM
Schechter, MT
McGillivray, BC
Gallagher, RP
Citation: Cd. Bajdik et al., A computer model to simulate family history of breast/ovarian cancer in BRCA1 mutation carriers, MATH BIOSCI, 171(1), 2001, pp. 99-111
Citation: Jm. Raboud et al., Predicting HIV RNA virologic outcome at 52-weeks follow-up in antiretroviral clinical trials, J ACQ IMM D, 24(5), 2000, pp. 433-439
Authors:
Singer, J
Thorne, A
Khorasheh, S
Raboud, JM
Wu, AW
Salit, I
Tsoukas, CM
Lemieux, C
Shafran, SD
Citation: J. Singer et al., Symptomatic and health status outcomes in the Canadian randomized MAC treatment trial (CTN010), INT J STD A, 11(4), 2000, pp. 212-219
Authors:
Montaner, JSG
Mo, T
Raboud, JM
Rae, S
Alexander, CS
Zala, C
Rouleau, D
Harrigan, PR
Citation: Jsg. Montaner et al., Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine, J INFEC DIS, 181(2), 2000, pp. 729-732
Authors:
Raboud, JM
Rae, S
Vella, S
Harrigan, PR
Bucciardini, R
Fragola, V
Ricciardulli, D
Montaner, JSG
Citation: Jm. Raboud et al., Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV, J ACQ IMM D, 22(3), 1999, pp. 260-266
Authors:
Raboud, JM
Rae, S
Hogg, RS
Yip, B
Sherlock, CH
Harrigan, PR
O'Shaughnessy, MV
Montaner, JSG
Citation: Jm. Raboud et al., Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation, J INFEC DIS, 180(4), 1999, pp. 1347-1350